首页/数据集/BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or Menin inhibitor

BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or Menin inhibitor

NIAID Data Ecosystem2026-05-02 收录

急性髓系白血病药物靶点

联合用药临床前疗效

数据链接：

https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE252938 数据链接链接失效反馈

官方服务：

资源简介：

This SuperSeries is composed of the SubSeries listed below. Refer to individual Series

应用场景：

创建时间：

2025-03-19

急性髓系白血病药物靶点

转录因子富集

Transcription Factor Enrichment Analysis of Differentially Downregulated Genes by The Drug Combination Previously Identified as Depleting Genes in a Genome-Wide CRISPR Dropout Screen

NIAID Data Ecosystem80

Structure of human MTHFD2 in complex with TH9619

MTHFD2-抑制剂复合物结构

急性髓系白血病药物靶点

Structure of human MTHFD2 in complex with TH9619 Descriptor: (E,4S)-4-[[5-[2-[2,6-bis(azanyl)-4-oxidanylidene-1H-pyrimidin-5-yl]ethanoylamino]-3-fluoranyl-pyridin-2-yl]carbonylamino]pent-2-enedioic ac

Protein Data Bank Japan2024-06-19 更新70

Expression profiling by high throughput sequencing of THP-1 cells treated with AT or HA

急性髓系白血病药物靶点

转录组药物响应

Deregulation of transcription factor MYB contributes to the development of leukemia and other human cancers, making MYB an attractive target for drug development. We demonstrate that the natural sesqu

NIAID Data Ecosystem40

Selective inhibition of the second bromodomain of BET family proteins results in robust antitumor activity in preclinical models of acute myeloid leukemia

急性髓系白血病药物靶点

BET蛋白抑制与表观遗传调控

Selective inhibition of the second bromodomain of BET family proteins is efficacious in preclinical models of AML Overall design: BRD4 ChIP-Seq under three different treatment conditions, H3K27Ac ChIP

NIAID Data Ecosystem80

Inhibitors of LSD1 target demethylase-independent activity to induce differentiation in acute myeloid leukemia [RNA-Seq experiments]. Homo sapiens

急性髓系白血病药物靶点

表观遗传调控

To determine whether changes in histone modifications directly correlate with changes in transcription, THP1 AML cells were treated with a potent and selective LSD1 inhibitor (OG86) and then subjected

NIAID Data Ecosystem50

BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or Menin inhibitor

资源简介：

相关数据集